AZ CEO does some bragging on U.K.'s Cambridge; Merck quits using chimps in biomedical research;

@FiercePharma: Daiichi Sankyo pledges 'drastic measures' to get Ranbaxy in line. Story | Follow @FiercePharma

@TracyStaton: BMS counts on DTC to keep driving Eliquis growth. But are its ads much different from rivals? News | Follow @TracyStaton

@EricPFierce: Lilly announced 1,000 job cuts in 2013. 2014 expected to be even bleaker. Report | Follow @EricPFierce

@CarlyHFierce: Sanofi wards off Lilly's Lantus challenger with infringement lawsuit. More | Follow @CarlyHFierce

> Valeant ($VRX) said the FDA has approved its supplemental application for Retin-A Micro Gel microsphere 0.08%, a topical treatment for acne. Item

> AstraZeneca ($AZN) CEO Pascal Soriot has done some bragging on the Cambridge, U.K. pharma technology cluster, saying it now "rivals the likes of San Francisco and Boston." Story

> Novo Nordisk ($NVO) said it has promoted Eddie Williams to senior vice president of biopharmaceuticals, an area of business it says will take on greater importance for the Denmark-based company. Report

> Actavis is realligning its structure. Story 

> U.S. Representative Henry Waxman (D-CA), who worked to strengthen the powers of the FDA, will retired at the end of the year after 40 years in Congress. Story (sub. req.)

Medical Device News

@FierceMedDev: Accuray rebound continues with strong second-quarter results Story | Follow @FierceMedDev

@MarkHFierce: Medtronic's Infuse bone growth product continues to generate legal problems. Report via MassDevice | Follow @MarkHFierce

@GalenMoore: At VentureCafe today: quantumvr's handheld 3D scanner. Design, sure, but could it be used for diabetes? Photo | Follow @GalenMoore

@EmilyWFierce: FDA considering faster approval process for high-need medical devices. Report via MedPageToday | Follow @EmilyWFierce

> Abiomed's heart pump wins Chinese approval as revenue soars. Story

> Despite modest growth, Cepheid swings to a loss in Q4. Article

Biotech News

@FierceBiotech: Bioinformatics skills help Stanford beat Illumina to $40M stell cell genomics grant. Story from FierceBiotech IT | Follow @FierceBiotech

@JohnCFierce: Amgen clocks 5th straight win on PCSK9, well ahead of the competition. Credit where it's due - they went all out. Story | Follow @JohnCFierce

@DamianFierce: AbbVie's hep C program is in desperate need of a catchy nickname. "ABT-450/r + ABT-267 + ABT-333" less than rolls off the tongue. | Follow @DamianFierce

@EmilyMFierce: Exposure to acid turns regular adult cells into stem cells. Story from FierceBiotech Research | Follow @EmilyMFierce

> AbbVie's hep C hopeful aces PhIII and sets off an arms race with Gilead. Story

> Two biotech IPOs blast off, spurring dreams--and fears--of an attempted gold rush. Article

> Sanofi blocks Eli Lilly's biosimilar of Lantus at the goal line, buys time. Story

> Amgen outpaces its rivals in the race for a PCSK9 blockbuster. News

> Wellcome ponies up $20M to kick-start an Oxford spinout. Article

And Finally... Merck ($MRK), among the last holdouts still using chimps in biomedical research, has ended the practice once and for all. Story (sub. req.)

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.